Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status.
Alimena
G
G
Breccia
M
M
Mancini
M
M
Diverio
D
D
Nanni
M
M
De Propris
M S
MS
Cimino
G
G
Pane
F
F
Mandelli
F
F
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy / Q000235:genetics*; D020134:Catalytic Domain; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017384:Sequence Deletion; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016315:Proto-Oncogene Proteins c-abl